BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001
January 20, 2022 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Jan. 20, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001
January 18, 2022 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
BetterLife Obtains Positive TD-0148A Data in Preclinical Models of Depression
December 09, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
H.C. Wainwright 2nd Annual Psychedelics Conference, BACK TO THE FUTURE!
December 03, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Dec. 03, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
BetterLife Obtains TD-0148A Behavioural Pharmacology Data Confirming its Projected Non-hallucinogenic Property
November 16, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Developing Psychedelic Medicine Beyond What We Already Know!
November 05, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Nov. 05, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
BetterLife Obtains TD-0148A In Vitro Pharmacology Data Confirming its Activity in Key Receptors Implicated in Depression and Neuropathic Pain
November 04, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
BetterLife Obtains TD-0148A Receptor Binding Data for IND-Enabling Pharmacology Studies
September 29, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Sept. 29, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
BetterLife Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders
September 27, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Sept. 27, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
BetterLife to Present at the Emerging Growth Conference on September 15, 2021
September 13, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Sept. 13, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotechnology company...